AI assistant
Axogen, Inc. — Director's Dealing 2017
Dec 21, 2017
32414_dirs_2017-12-20_919ced09-cf90-4c22-94f0-50cfadfa2489.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AxoGen, Inc. (AXGN)
CIK: 0000805928
Period of Report: 2017-12-18
Reporting Person: Gingrich Jon S. (Chief Commercial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-12-18 | Employee Stock Option (right to purchase) | $27.00 | A | 32600 | Acquired | 2027-12-18 | Common Stock (32600) | Direct |
| 2017-12-18 | Restricted Stock Units | $ | A | 5500 | Acquired | Common Stock (5500) | Direct |
Footnotes
F1: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 18, 2021 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.
F2: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.
F3: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.